Roivant Sciences’ (ROIV) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Roivant Sciences (NASDAQ:ROIV) in a report published on Thursday, Benzinga reports.

ROIV has been the subject of a number of other research reports. Bank of America boosted their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a neutral rating in a report on Wednesday, September 11th. HC Wainwright reissued a buy rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Thursday. Finally, Piper Sandler raised their price objective on Roivant Sciences from $20.00 to $22.00 and gave the stock an overweight rating in a research note on Wednesday, July 10th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Roivant Sciences has a consensus rating of Moderate Buy and a consensus target price of $17.39.

Roivant Sciences Stock Performance

ROIV stock opened at $11.97 on Thursday. Roivant Sciences has a twelve month low of $8.24 and a twelve month high of $13.24. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. The company has a market cap of $8.84 billion, a P/E ratio of 2.37 and a beta of 1.25. The business’s fifty day moving average is $11.46 and its 200-day moving average is $11.05.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. The firm had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The company’s revenue was up 155.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.38) earnings per share. Equities research analysts forecast that Roivant Sciences will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP lifted its position in shares of Roivant Sciences by 81.0% during the 4th quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock worth $213,370,000 after buying an additional 8,500,000 shares in the last quarter. Norges Bank bought a new stake in Roivant Sciences during the fourth quarter worth $41,506,000. Troluce Capital Advisors LLC purchased a new position in Roivant Sciences in the second quarter worth $31,182,000. First Trust Advisors LP grew its stake in Roivant Sciences by 434.8% in the 4th quarter. First Trust Advisors LP now owns 2,739,438 shares of the company’s stock valued at $30,764,000 after purchasing an additional 2,227,192 shares during the period. Finally, Penn Davis Mcfarland Inc. bought a new position in Roivant Sciences in the 1st quarter valued at $17,287,000. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.